Many cannabidiol (CBD) products are available for sale in the U.S., yet few of them are supported by evidence on safety or optimal uses. Use of CBD products is growing among older adults. Chronic conditions may lead them to seek alternative approaches to manage pain, insomnia, anxiety, and some symptoms of Alzheimer’s or Parkinson’s disease. In fall 2020, GSA convened stakeholders representing seven patient advocacy groups and 10 professional societies to discuss federal and state law governing cannabis-derived products to the safety of the medical use of these products by adults aged 55 years or older. This publication summarizes presentations and recommendations by the stakeholders.

The use of cannabis among older adults is increasing in the United States. While cannabis use has been suggested to help alleviate chronic symptoms experienced by older adults, its potential adverse effects may lead to unintended consequences, including increased acute healthcare utilization related to its use. This GSA Policy Profile delves into what has happened in the environment since 2021 when GSA published Medical Use of Cannabidiol in Older Adults, which was based on a convening of experts in pharmacy, clinical medicine, research, law, and policy. 

Additional Resources:

• Common Terminology & Glossary (April 2023 Version)
• Cannabis Infographic
• FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)
• Download the Transcript

Support provided by Jazz Pharmaceuticals.